Outcomes of primary refractory multiple myeloma and the impact of novel therapies

Bortezomib–thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials

(2014) Hejing Huang et al.   LEUKEMIA RESEARCH

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2012) Laurent Garderet et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

(2011) P. Moreau et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03

(2011) Susanna J. Jacobus et al.   BRITISH JOURNAL OF HAEMATOLOGY

Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials

(2011) Lida Wang et al.   HEMATOLOGICAL ONCOLOGY

Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data

(2011) D. Pulte et al.   ONCOLOGIST

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

(2010) P. Moreau et al.   BLOOD

Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study

(2010) Tiina M. Oivanen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

(2010) J.-L. Harousseau et al.   HAEMATOLOGICA

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

(2010) María-Victoria Mateos et al.   LANCET ONCOLOGY

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA